Pharmaceuticals Sector - Solvay

16
Solvay Global Annual Report 2005
Three priority directions have been
selected in response to these
changes.
Portfolio orientation:
greater selectivity in order to
increase our chances of success in
an ever more demanding regulatory
and medical environment.
– “Cardiometabolic” specialties and
“neuroscience” are now our main
areas of therapeutic interest. We
shall continue to invest in every
aspect of them, from research
and development (R&D) through
to global marketing. We are also
actively seeking licensing agreements
with which to balance out
and increase our coverage of this
area.
– Flu vaccines and pancreatic
enzymes directly linked to unmet
medical needs will be the subject
of targeted investments, including
R&D and licensing agreements.
– We shall be progressively
de-emphasizing research in male
and female hormone treatments.
These will constitute a downstream
activity, concentrated
on marketing and supported by
licence buy-ins and acquisitions.
Performance objectives:
We have clearly defi ned the
changes we need to make and
the timetables we need to adhere
to in order to achieve our 2010
objectives.
Clearly specifi ed targets will
enable us to develop a long-term
product line which meets the
needs of the medical world and of
external players like the fi nancial
community.
A global organization:
To attain these performance goals,
the organization has been redefi -
ned with a global vision, aimed at
achieving or exceeding reference
values for effi ciency and effectiveness
in each functional area.
The organization will be optimized
to take it past the critical size
threshold, whilst remaining light
and fl exible in order to adapt and
change faster and better than
many other players.
Development
by individual
therapeutic fi elds
and geographic
areas
The results for the Sector include
those of Fournier Pharma since
August 1, 2005. Sales are up 30%
on 2004. Without Fournier Pharma
they would have been up 15%.
These growth rates are above
those of the pharmaceutical
industry as a whole.
The United States remains our
largest market with 33% of sales.
These were up by 39%, including
Fournier Pharma.
Apart from a handful of countries,
sales in Western Europe recovered
signifi cantly from 2004.
In Russia they leapt forward a
spectacular 80% thanks to greater
geographic coverage and
the introduction of a national
reimbursement system.
Growth was sustained in South
Africa, Australia and the Middle
East and in our priority
development zones of Brazil
and Canada.
We are paying increasing attention
to Asia, where our sales remain
modest, but where our growth
rate is high.
“ Sales are up
30% on 2004.”